Skip to main content
. 2015 Apr 14;6(15):13790–13802. doi: 10.18632/oncotarget.3831

Figure 5. ARPCA inhibits the in vivo growth of FGF8b/FGF2/DHT-regulated TRAMP-C2 tumors.

Figure 5

A. C57BL/6 male mice were implanted s.c. with alginate plugs containing TRAMP-C2 cells and treated i.p. every other day with 100 mg/kg of ARPCA or ARPVA (6 mice/group). After one week of treatment, plugs were harvested and processed for FGFR1, pFGFR1, Ki67 and CD31 immunofluorescence analysis. Scale bars: 30 μm (FGFR1 and pFGFR1) and 100 μm (H&E, Ki67, CD31). Intensity of pFGFR1/FGFR1 signal and Ki67+ or CD31+ areas were quantified and normalized to DAPI area (DAPI is in blue). B. Long-term tumor growth of TRAMP-C2 cells grafted s.c. in C57BL/6 male mice treated i.p. with vehicle or 100 mg/kg ARPCA or ARPVA. Treatments are indicated by arrows. At the end of the experiment, tumors were harvested, photographed and weighted (10-12 mice/group). Data are the mean ± SEM; ** < 0.01, #P < 0.001.